General Information of Drug (ID: DM3YEV0)

Drug Name
131I-labelled aCD45 Drug Info
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DM3YEV0

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Iomab-B DMZA47Y Acute myeloid leukaemia 2A60 Phase 3 [3]
[131I]-BC8 DMV86DY leukaemia 2A60-2B33 Phase 2 [4]
LM-CD45 DMR7LKC Transplant rejection NE84 Phase 1 [5]
Anti-CD45 mabs DMZ2D0G Lymphoma 2A80-2A86 Phase 1 [6]
Iomab-ACT DMY0QL7 B-cell acute lymphoblastic leukaemia 2B33.3 Phase 1 [7]
OX-30 DMVPG1N Pain MG30-MG3Z Terminated [8]
Asp-BrPmp-Leu DMJEZ62 Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukocyte common antigen (PTPRC) TTUS45N PTPRC_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT02665065) Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA). U.S. National Institutes of Health.
2 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 2006 Mar 1;107(5):2184-91.
3 Clinical pipeline report, company report or official report of Actinium Pharmaceuticals.
4 Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood. 1995 Feb 15;85(4):1122-31.
5 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002932)
6 CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells. Haematologica. 2006 Jul;91(7):886-94.
7 Clinical pipeline report, company report or official report of Actinium Pharmaceuticals.
8 CD45 / PTPRC Antibody, Biotin conjugate (OX-30).
9 A protected l-bromophosphonomethylphenylalanine amino acid derivative (BrPmp) for synthesis of irreversible protein tyrosine phosphatase inhibitors. Bioorg Med Chem. 2010 Dec 15;18(24):8679-86.